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Introduction: Gemcitabine, the current standard of care for pancreatic ductal adenocarcinoma (PDA),
has a less than 10% partial response rate. Genexol-PM, a modified form of paclitaxel, has been shown
to have antitumour effects in clinical trials of metastatic breast and small-lung-cell carcinoma. The aim of
the present study was to determine if Genexol would be a beneficial treatment for gemcitabine-resistant
PDA.
Materials and methods: We measured the in vitro IC50s of gemcitabine and genexol in cell lines
sensitive and resistant to gemcitabine. In vivo, animals with orthotopic pancreatic tumours, resistant
to gemcitabine, were treated with phosphate-buffered saline (PBS), gemcitabine, Genexol or
gemcitabine+Genexol. Tumour progression was monitored using red fluorescent protein imaging.
Results: We showed equivalent IC50s for gemcitabine-sensitive and gemcitabine-resistant cell lines
when treated with genexol. In vivo treatment with genexol resulted in a greater per cent reduction in
tumour size, less metastatic spread and longer survival compared with treatment with gemcitabine.
Discussion: Genexol proved to be an effective treatment for gemcitabine-resistant PDA. These data
combined with the successful clinical use of genexol in Phase II trials of other malignancies suggests
it maybe an effective treatment for pancreatic cancer, specifically for those patients resistant to
gemcitabine.
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Introduction
Pancreatic ductal adenocarcinoma (PDA) is an exceptionally
lethal disease, with approximately 80% of patients presenting with
unresectable disease as a result of metastases and local invasion.1
While survival in many cancers, including breast and colon, have
increased as the result of advances in solid tumour therapies, it has
been estimated that the overall 5-year survival rate for patients
with pancreatic cancer is only 5%.2
The main line of defence against pancreatic cancer is gemcit-
abine, a nucleoside analogue, which stops tumour growth by
blocking DNA synthesis.Although gemcitabine is a relatively well-
tolerated drug, acquired as well as an initial non-response in PDA
patients is a major limitation of this line of therapy.3 The median
survival with advanced disease remains less than 6 months, the
overall tumour response rate is less than 25% and mean survival
benefit when given post-surgical resection is 6–8 months.3,4 Taken
together the data suggests that a novel treatment that acts through
a different pathway would offer advantages, as it could potentially
work on those individuals that do not respond to gemcitabine, as
well as those that acquire a resistance to gemcitabine.
One potential novel drug is Genexol. Genexol is a modified
form of paclitaxel, which does not have the same toxicity problems
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that are encountered when treating with paclitaxel. The mecha-
nism of action of Genexol at the cellular level is the stabilization of
microtubules, thus preventing cell division. To date clinical trials
with Genexol for the treatment of advanced malignancies,
advanced small-cell-lung cancer and metastatic breast cancer have
been promising.5–7
In terms of pancreatic cancer, there is preliminary data in vitro
and in an animal model that suggests Genexol could be advanta-
geous as a treatment regimen for pancreatic cancer.8 The results of
a Phase II trial for the treatment of locally invasive and metastatic
PDA patients was recently published, with a median overall sur-
vival of 6.5 months.9 Therefore, the aim of the present study is to
examine Genexol as a potential treatment for gemcitabine-
resistant pancreatic cancer in vitro and with an orthotopic animal
model.
Materials and methods
Cell culture
The human pancreatic cancer cell line MiaPaCa-2 was obtained
from the American Type Culture Collection (Rockville, MD,
USA). Cells were maintained in Dulbecco’s Modified Eagle
Medium (DMEM) supplemented with 10% heat-inactivated fetal
bovine serum (FBS; Gibco, Grand Island, NY, USA). Cells were
cultured at 37°C in a 5%CO2 incubator. TheMiaPaCa-2 cells were
engineered to stably express red fluorescent protein (Clontech,
Palo Alto, CA), as previously described.10,11 After stable transfec-
tion of red fluorescent protein (RFP), gemcitabine-resistant cells
(GEM-MiaPaCa-2) were generated.12–14 We have consistently
shown that repeated passages of our MiaPaCa-2 cells results in a
gemcitabine-resistant cell line, without exposure to gemcitabine.15
We initially conducted an in vitro study to demonstrate that our
cell line is resistant to gemcitabine.
Drug sensitivity
The two cell lines, GEM-MiaPaCa-2 and MiaPaCa-2, were subse-
quently exposed to serial dilutions of gemcitabine, paclitaxel, and
Genexol to determine their respective IC50s. Specifically,
500 000 cell/well were plated onto a 96-well plate, allowed to
adhere for 24 h and then exposed to fresh drug and media every
day for 72 h. The dosages of gemcitabine were 0, 3.9 nM, 7.8 nM,
15.6 nM, 31.25 nM, 62.5 nM, 125 nM, 250 nM, 500 nM and
1000 nM. The serial dosages for paclitaxel (Sigma-Aldrich, St.
Louis, MO, USA) and Genexol (Samyang Corp, Daejeon, South
Korea) were 0, 0.625 nM, 1.25 nM, 2.5 nM, 5 nM, 10 nM, 20 nM,
40 nM and 80 nM. At 72 h cells were incubated in a 10% alamar-
Blue solution (Invitrogen, Carisbad, CA,USA) for 2 h at 37°C, and
then fluorescence read (FLx800; BioTek, Winooski, VT, USA)
according to the manufacturer’s instructions. IC50s were then
determined using commercially available software (CalcuSyn,
Cambridge, UK). All experiments were done in triplicate.
Surgical procedures
Thirty male nude mice between 4 and 6 weeks of age were main-
tained in a barrier facility equipped with HEPA-filtered racks. All
studies were conducted with the approval and guidance of the
University of Utah Institutional Animal Care and Use Committee.
The orthotopic tumour induction surgery was performed as pre-
viously described.10,11 Briefly, 1.5 ¥ 106 RFP expressing GEM-
MiaPaCa-2 cells suspended in 150 ml of serum-free media were
injected into the tail of the pancreas via a left subcostal incision.
The abdomen was closed using 6-0 silk sutures closing both skin
and muscle simultaneously. All procedures were done under
aseptic conditions.
Imaging
After the primary surgery, high resolution (3456 ¥ 2304 pixels)
whole body digital images (EOS Digital Rebel, Canon USA, Lake
Success, NY, USA) of each mouse were obtained once a week to
monitor primary tumour growth.We have previously showed that
the RFP tumour area is linearly correlated with tumour mass.10,11
The RFP was visualized with an Illumatool Bright Light System
that consisted of a 563-nm excitation filter and a 587-nm viewing
filter (Model LT-9900, LightTools Research, Encinitas, CA, USA).
Animals were imaged under nose-cone induced isoflurane general
anaesthesia. Primary tumour area was quantified using public
domain software (National Institutes of Health ImageJ; http://
rsb.info.nih.gov/ij/).
Treatment
At 4 weeks post-tumour induction 27 of the 30 animals had con-
firmed tumours, as determined by RFP imaging. Animals with
tumours were randomly assigned to one of four groups: Control
(Saline), Gemcitabine (3.5 mg/200 ml/animal), Genexol (0.5 mg/
200 ml/animal) and Gemcitabine+Genexol (3.5 mg/200 ml/animal
and 0.5 mg/200 ml/animal, respectively). The animals were treated
twice a week for 2 weeks, followed by 2 weeks of no treatment, and
then subsequently retreated twice a week for 2 weeks (Fig. 1).
Tumour size was monitored weekly and when the tumour reached
roughly 2 cm in diameter the animal was necropsied.
At necropsy, after in vivo imaging, the primary tumour was
removed and weighed. Additionally, all metastases were located
and sites of metastases noted, as well as a sample removed. All
removed tumours and metastases were fixed in 10%formalin,
embedded in paraffin and stained for histological analysis. RFP
imaging was utilized to confirm the presence and location of any
metastasis.
Statistics
Group differences for final tumour mass, survival, number of
metastatic sites and percent reduction in tumour size were com-
pared utilizing an ANOVA followed by Tukey’s post-hoc test.
Weekly tumour size as determined by RFP imaging was compared
between the groups with a repeated measure ANOVA followed by
a post-hoc test. A P-value of <0.05 was considered significant.
Results
In vitro IC50s
As expected the IC50 for GEM-MiaPaCa-2 (331 42 nM) was
considerably higher, 10-fold, than our original wild-type
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MiaPaCa-2 cell lines (30 2 nM) (Table 1). The IC50 for pacli-
taxel was significantly less than gemcitabine and Genexol, with no
differences between the two cell lines. Additionally, the IC50 for
Genexol was less than half the dose of gemcitabine, 13 nM com-
pared with 30 nM. Thus, both cell lines appear to be equally
sensitive to paclitaxel and Genexol and the IC50 dose for paclitaxel
and Genexol is smaller than gemcitabine.
In vivo weekly tumour area
There were no differences between the four groups in terms of
initial tumour area as measured by RFP imaging (Table 2).
However, at the end of the first 2 weeks of treatment there were
marked differences in tumour RFP area between the groups
(Fig. 2). Specifically, at week three both the Control
(429 113 mm2) and Gemcitabine (354 76 mm2) groups had
significantly larger tumours than the Genexol (44 47 mm2) and
Gemcitabine+Genexol (34 49 mm2) groups. The size of the
Control and Gemcitabine groups’ tumours had increased
57 17% and 57 9% relative to their starting areas by week
three, respectively. While the tumours in the Genexol group had
shrunk by 64 38% and the Gemcitabine + Genexol had
decreased by 84 17%, all of the tumours in the Control and
Gemcitabine groups had reached 2 cm at 4 weeks, thus the
animals in these two groups did not receive the second round of
treatment. Although the Genexol-treated groups manifested sig-
nificant tumour regression during the first 2 weeks of treatment,
the second 2-week treatment did not cause regression of residual
tumours (Fig. 2). By week 7 the tumours in both the Genexol and
Gemcitabine+Genexol groups were increasing in size. There were
no differences in terms of absolute, relative or per cent change in
tumour area between the Genexol and Gemcitabine+Genexol
groups at anytime point.
Survival
There was a clear difference in the survival of the Control (43 5
days) and Gemcitabine (46 4 days) groups compared with the
Genexol (107 32 days) and Gemcitabine+Genexol groups
(103 15 days) (Table 2; Fig. 3). Four weeks after the initiation
of treatment all of the tumours in the Control and Gemcitabine
groups had reached 2 cm.The Genexol andGemcitabine+Genexol
groups had a mean survival of 15 weeks (Table 2).
Tumour burden
The final tumour area as measured with RFP and the final tumour
mass did not differ between the four groups. In terms of
metastases, 100% of the Control and Gemcitabine animals had
metastases at necropsy, compared with 71% of the Genexol and
84% of the Gemcitabine+Genexol. The most frequent sites of
metastases, irrespective of group, were the mesentery, diaphragm,
liver and kidney. The Control (3.7 1) and Gemcitabine
(3.8 0.4) groups had statistically more sites of metastases com-
pared with the Genexol (1.6 1.3) and Gemcitabine+Genexol
(2.2 1.5) groups. Roughly 70% of the animals in the Control,
Gemcitabine and Gemcitabine+Genexol groups had ascites at
necropsy, whereas only 42% of the animals in the Genexol groups
had ascites.
Discussion
We have shown in the present study that Genexol is a potential
drug to treat gemcitabine-resistant pancreatic adenocarcinoma.
Initially we confirmed that our GEM-MiaPaCa-2 cells were resis-
tant to gemcitabine, as GEM-MiaPaCa-2 cells had an IC50 that
was ten times greater than our original MiaPaCa-2 cells. Next,
we demonstrated equivalent IC50s for Genexol in the two cell
lines. To confirm our in vitro data we compared gemcitabine,
Genexol and the two in combination as a treatment in an ortho-
topic animal model of pancreatic cancer. There were dramatic
differences in the response to treatment with a per cent reduc-
tion in tumour size, as measured by RFP, number of metastases
and survival all showing more positive results with Genexol
treatment.
These results are important, as gemcitabine resistance is a
major problem in the treatment of pancreatic cancer. Less than
10% of pancreatic adenocarcinoma patients undergoing gemcit-
abine treatment show a partial response.4 As gemcitabine is cur-
rently the gold standard of care, resistance is a dramatic
problem. There are several mechanisms by which pancreatic
cancer can acquire resistance to gemcitabine. Numerous studies
have shown a positive correlation between hENT1, the main
nuclear transporter that brings gemcitabine into the cell, and
Treatment
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Figure 1 Experimental timeline. Animals were treated twice, both for two times a week for 2 weeks. The endpoint was defined as when the
tumour reached 2 cm in diameter as measured with red fluorescent protein (RFP) imaging
Table 1 In vitro IC50s* for three different drug formulations
Cell lines Gemcitabine Taxol Genexol
MiaPaCa2 29.6  1.7 5.5  0.8 13.7  3.8
GEM-MiaPaCa2 330.5  42.2 4.5  0.8 13.1  4.2
*All dosages in nM.
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survival, as well as gemcitabine sensitivity.16–18 Other mediators
of gemcitabine resistance include deoxycytidine kinase and ribo-
nucleotide reductase.19,20 Reductions in the function of these
kinases results in an increase in gemcitabine resistance, as both
are important components in the metabolism of gemcitabine.
Alhough the elucidation of the mechanism of gemcitabine resis-
tance is beyond the scope of the present study, we show that cells
resistant to gemcitabine are sensitive to Genexol, both in vitro
and in vivo. Thus, Genexol maybe an important second line of
defence in the treatment of pancreatic cancer, as the animals
treated with Genexol survived on average three times as long as
those treated with gemcitabine.
The mechanism of action of gemcitabine differs from that of
Genexol and paclitaxel. Gemcitabine acts by stabilizing DNA.3 In
contrast, Genexol and paclitaxel stabilize microtubules.6,21 Thus,
Gemcitabine acts at the genetic level by preventing the replica-
tion of DNA, where as Genexol and paclitaxel physically prevent
the cells from dividing by stabilizing the microtubules. Genexol
may be advantageous to use as a treatment regimen compared
with paclitaxel. The micelle formulation of Genexol alleviates the
need to use Cremophor EL, thus reducing the cytotoxicity of the
drug.6 Paclitaxel has poor water solubility, so Cremophor EL is
required to increase the solubility of the drug to allow for
systemic delivery. However, Cremophor EL is also associated
with toxicity.22 Genexol has a larger maximum tolerated
dose than paclitaxel, probably the result of the different
formulations.6
Given these benefits of Genexol there have been several clinical
trials evaluating the efficacy of Genexol. In the Phase II trial for
metastatic breast cancer 24 of the 41 patients (59.5%) were either
complete or partial responders, with a median time to progression
of 9 months. A Phase II trial for patients with advanced non-
small-cell lung caner, reported a response rate of 37.7%.5 The
clinical trials suggest that Genexol maybe a beneficial chemo-
therapy agent for the treatment of PDA, as such a Phase II trial has
recently been published. Patients with metastatic or locally inva-
sive PDA were treated with Genexol at a dose of 300 mg/m2 every
3 weeks.9 The disease control rate was 65%, with a medial overall
survival of 6.5 months. The present investigation suggests the
Genexol could also be a useful treatment option for PDA patients
that are insensitive to gemcitabine.
Table 2 In vivo experimental endpoints for the different treatment regimens
Group Initial tumour
area (mm^2)
Final tumour
area (mm^2)
Final tumour
mass (g)
Survival
(days)
Per cent
metastasize
Control 148  59 367  89 4.0  1.4 43  5* 100*
Gemcitabine 151  50 364  82 3.4  1.2 46  4* 100*
Genexol 137  50 317  101 3.8  1.5 107  32 71
Gemcitabine+Genexol 175  64 367  43 3.9  1.1 103  15 84
*Statistically different from Genexol and Gemcitabine+Genexol; P < 0.05.
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Conclusion
Gemcitabine resistance is a major obstacle in the treatment of
PDA. Genexol treatment resulted in a reduction in tumour mass,
as measured by RFP, a reduction in the incidence of metastases
and increased survival in a gemcitabine-resistant orthotopic
animal model of PDA. Clinical trials for the treatment of meta-
static breast cancer and non-small-cell lung cancer, accompanied
by the data presented here suggest that Genexol could be a good
second line of defence against pancreatic cancer, specifically for
patients resistant to gemcitabine.
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